Physician profile
Daljit S Mac
NPI 1871500363
$28,750.89
in general payments reported to CMS, 2019-2025
35 companies · $4,611 in 2025
The $4,611 reported for 2025 was more than what 94% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,463 · 2020: $2,544 · 2021: $3,898 · 2022: $4,530 · 2023: $4,079 · 2024: $4,626 · 2025: $4,611.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $13K · Education: $11.31.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $13,304.24 |
| Education | $11.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $5,835.80 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $2,238.12 | 2019-2025 | Rexulti, Nuedexta, Abilify Asimtufii |
| Allergan, INC. | $2,111.05 | 2019-2020 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,923.92 | 2021-2025 | Caplyta |
| Sunovion Pharmaceuticals INC. | $1,884.96 | 2019-2022 | |
| Lundbeck LLC | $1,606.36 | 2019-2025 | Rexulti |
| Tris Pharma INC | $1,458.55 | 2019-2025 | Dyanavel Xr, Onyda Xr, Quillivant |
| Axsome Therapeutics, INC. | $1,358.45 | 2023-2025 | Auvelity, Sunosi |
| Supernus Pharmaceuticals, INC. | $1,074.80 | 2021-2025 | Qelbree, Qelbree |
| Takeda Pharmaceuticals U.S.A., INC. | $1,067.00 | 2019-2025 | Trintellix |
| Alkermes, INC. | $989.35 | 2022-2025 | Lybalvi, Aristada |
| Neurocrine Biosciences, INC. | $891.95 | 2019-2025 | Ingrezza |
| Vanda Pharmaceuticals INC. | $723.58 | 2019-2025 | Fanapt, Hetlioz |
| Avanir Pharmaceuticals, INC. | $701.27 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $700.57 | 2019-2025 | Spravato |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $653.79 | 2019-2024 | Austedo Xr, Uzedy |
| Corium, LLC | $473.07 | 2022-2025 | Azstarys |
| Bausch Health US, LLC | $453.33 | 2019-2025 | Aplenzin, Wellbutrin |
| Neos Therapeutics, LP | $439.42 | 2019-2025 | Adzenys Xr-Odt, Exxua |
| Merck Sharp & Dohme LLC | $259.71 | 2020-2023 | Belsomra |
| E.R. Squibb & Sons, L.L.C. | $242.91 | 2025 | Cobenfy |
| Eisai INC. | $211.99 | 2020-2021 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $210.95 | 2021-2022 | |
| Idorsia Pharmaceuticals US INC | $208.27 | 2023 | Quviviq |
| Ironshore Pharmaceuticals INC. | $204.30 | 2020-2024 | |
| Biohaven Pharmaceuticals, INC. | $173.66 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $145.50 | 2022 | |
| Arbor Pharmaceuticals, INC. | $123.51 | 2019-2021 | |
| Biogen, INC. | $81.00 | 2024 | Zurzuvae |
| Noven Therapeutics, LLC | $79.89 | 2023-2025 | Xelstrym |
| Collegium Pharmaceutical, INC. | $65.21 | 2025 | Jornay Pm |
| Adlon Therapeutics L.P. | $56.58 | 2019-2021 | |
| Sage Therapeutics, LLC | $46.56 | 2024-2025 | Zurzuvae |
| Azurity Pharmaceuticals, INC. | $33.24 | 2023-2025 | Horizant, Horizant |
| Jazz Pharmaceuticals INC. | $22.27 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daljit Mac listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.